Financial intelligence for Asia's healthcare markets
Remember me:

News articles    

ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics has signed a $10 million Series B Plus strategic financing round from Shanghai Healthcare Capital.
Shanghai-based 111 Inc, an integrated online and offline healthcare platform, today announced its results for the second quarter of 2020, as well as a significant capital injection.
Beijing-based China Biologic Products Holdings, a plasma-based biopharmaceutical company, announced its net income decreased by 14.2% to $35.7 million from $41.6 million in the same quarter of 2019.
Huami Corporation, a healthcare services provider and smart wearable technology company, has announced second quarter net income of ¥13.3 million ($1.9 million).
Shanghai-based cardiac device company Hanyu Medical has completed a ¥500 million ($72.05 million) Series D round financing co-led by Highlight Capital, CITIC Private Equity Funds Management, and Yingke PE.
China Pharma Holdings, an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, has announced net income of $13,000 for the second quarter of 2020.
WuXi AppTec Co, which provides a broad portfolio of R&D and manufacturing services for companies in the pharmaceutical, biotech and medical device industries, has announced Q2 profit of ¥1.4 million ($204.8 million).
Chinese clinical-stage antimicrobial drug developer MicuRx Pharmaceuticals has raised ¥300 million ($43.1 million) in a Series D funding roumd led by HG Capital.
Shanghai-based biotech firm Lepu Biotech has completed a ¥1.291 billion ($186 million) Series B funding round by Riverhead Capital, Sunshine Insurance Group and Ping An Capital.
ABM Therapeutics, has raised $20 million in a Series A+ funding round led by China Growth Capital.

Subscribe to our news RSS feed Get the RSS for HealthInvestor Asia




The IPO market in Hong Kong is hotting up again and it looks as though 2019 is going to be as busy with biotech company floats as last year was.



HealthInvestor Asia twitter feed


HealthInvestor UK